Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319541 | 0.92 | KDM4E (0.41) | SMN1; SMN2KDM4ECDK1ALDH1A1HSD17B10 | |
| SCHEMBL7332522 | 0.91 | KDM4E (0.40) | SMN1; SMN2KDM4ECDK1ALDH1A1HSD17B10 | |
| SCHEMBL1435852 | 0.86 | HSD17B10 (0.48) | SMN1; SMN2KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL2964763 | 0.84 | PARP1 (0.48) | KDM4EALDH1A1HSD17B10ALOX15MEN1 | |
| SCHEMBL12811926 | 0.83 | KDM4E (0.39) | SMN1; SMN2KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL856326 | 0.82 | TDP1 (0.43) | SMN1; SMN2KDM4ECDK1ALDH1A1HSD17B10 | |
| SCHEMBL9367664 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EALDH1A1LMNAALOX15 | |
| SCHEMBL15898897 | 0.80 | CA12 (0.44) | SMN1; SMN2KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL19125590 | 0.80 | MAOA (0.42) | SMN1; SMN2KDM4EALDH1A1HSD17B10LMNA | |
| SCHEMBL8126632 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2KDM4ECDK1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116082319-A | Continuous synthesis method of prucalopride succinate | 南京恒通医药开发有限公司 | 2023-05-09 | — | — | CN | claimed |
| CN-111620857-A | Continuous synthesis method of prucalopride succinate | 南京恒通医药开发有限公司 | 2020-09-04 | — | — | CN | claimed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| EP-3413891-A1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE AND ITS INTERMEDIATES | Symed Labs Limited (IN) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137910-A1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE AND ITS INTERMEDIATES | SYMED LABS LIMITED (IN) | 2017-08-17 | — | — | WO | claimed |
| EP-3413891-B1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE | SYMED LABS LTD (IN) | 2024-01-03 | — | — | EP | disclosed |
| CN-116082319-A | Continuous synthesis method of prucalopride succinate | 南京恒通医药开发有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111620857-A | Continuous synthesis method of prucalopride succinate | 南京恒通医药开发有限公司 | 2020-09-04 | — | — | CN | disclosed |
| CN-111298127-A | Composition comprising histamine release-promoting substance and inhibitory compound, and oral solid preparation containing the same | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| EP-3413891-A1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE AND ITS INTERMEDIATES | Symed Labs Limited (IN) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137910-A1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE AND ITS INTERMEDIATES | SYMED LABS LIMITED (IN) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137910-A1 | PROCESSES FOR THE PREPARATION OF HIGHLY PURE PRUCALOPRIDE SUCCINATE AND ITS INTERMEDIATES | SYMED LABS LIMITED (IN) | 2017-08-17 | — | — | WO | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1557165-A1 | COMBINATION DRUG | Eisai Co., Ltd. (JP) | 2005-07-27 | — | — | EP | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1506178-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-16 | — | — | US | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-29 | — | — | US | disclosed |
| WO-2003096980-A2 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019063-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | SMN1; SMN2 1069/4885KDM4E 1161/4885CDK1 772/4885 |
| US-20040181064-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | SMN1; SMN2 886/4885KDM4E 1539/4885CDK1 672/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | SMN1; SMN2 3923/4885KDM4E 2115/4885CDK1 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.